# Maximal Use Study to Determine the Pharmacokinetics of L-arginine After Exaggerated Oral Use of COL101

> **NCT06182267** · PHASE1 · COMPLETED · sponsor: **Colgate Palmolive** · enrollment: 29 (actual)

## Conditions studied

- Caries,Dental

## Interventions

- **DRUG:** L Arginine
- **DRUG:** Sodium Fluoride

## Key facts

- **NCT ID:** NCT06182267
- **Lead sponsor:** Colgate Palmolive
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-27
- **Primary completion:** 2023-12-22
- **Final completion:** 2023-12-22
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06182267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06182267, "Maximal Use Study to Determine the Pharmacokinetics of L-arginine After Exaggerated Oral Use of COL101". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06182267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*